Health Care & Life Sciences » Biotechnology | NewLink Genetics Corp.

NewLink Genetics Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,093.00
172,592.00
68,501.00
35,768.00
28,711.00
12,474
SG&A Expense
31,343.00
53,922.00
100,511.00
112,842.00
98,485.00
72,467
EBIT
31,141.00
117,573.00
33,602.00
79,158.00
71,181.00
61,138
Unusual Expense
-
-
-
11,600.00
1,700.00
1,300
Non Operating Income/Expense
112.00
-
14.00
32.00
126.00
102
Interest Expense
33.00
26.00
105.00
22.00
119.00
52
Pretax Income
31,050.00
117,633.00
33,643.00
90,511.00
72,510.00
60,563
Income Tax
130.00
14,775.00
6,738.00
5,356.00
559.00
6,968
Consolidated Net Income
31,180.00
102,858.00
40,381.00
85,155.00
71,951.00
53,595
Net Income
31,180.00
102,858.00
40,381.00
85,155.00
71,951.00
53,595
Net Income After Extraordinaries
31,180.00
102,858.00
40,381.00
85,155.00
71,951.00
53,595
Net Income Available to Common
31,180.00
102,858.00
40,381.00
85,155.00
71,951.00
53,595
EPS (Basic)
1.23
3.32
1.41
2.94
2.30
1.44
Basic Shares Outstanding
25,275.20
27,838.90
28,586.60
28,979.30
31,304.30
37,191.30
EPS (Diluted)
1.23
3.32
1.41
2.94
2.30
1.44
Diluted Shares Outstanding
25,275.20
31,025.10
28,586.60
28,979.30
31,304.30
37,191.30
EBITDA
30,250.00
118,670.00
32,010.00
77,074.00
69,774.00
59,993
Non-Operating Interest Income
12.00
86.00
78.00
237.00
616.00
2,029

About NewLink Genetics

View Profile
Address
2503 South Loop Drive
Ames Iowa 50010
United States
Employees -
Website http://www.newlinkgenetics.com
Updated 07/08/2019
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications.